QSAR in Development of Antidepressants
QSAR in Development of Antidepressants
QSAR in Development of Antidepressants
SHOW LESS
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Stagnant progression<br />
• Serious Drawback to SSRIs<br />
– delay <strong>of</strong> therapeutic benefit<br />
• two to six weeks for response<br />
– low rate <strong>of</strong> response<br />
– low rate <strong>of</strong> remission<br />
• Delayed response due to 5-HT 1a <strong>in</strong>hibition<br />
• 5-HT 1A desensitization normal fir<strong>in</strong>g<br />
– therapeutic effect
Change language